Navigation Links
Molecular basis for neurodegeneration in Ataxia telangiectasia
Date:4/14/2008

An upcoming paper from Dr. David Wassarman (University of Wisconsin School of Medicine and Public Health) in the May 1 issue of G&D lends new insight into the pathogenesis of neurodegeneration in Ataxia telangiectasia.

Ataxia telangiectasia (A-T) is a rare, genetic immunodeficiency disease that affects multiple organ systems and is characterized by neurodegeneration and cancer predisposition. A-T is caused by recessive mutations in the ataxia telangiectasia mutated (ATM) gene.

While existing animal models have established how ATM mutations contribute to genomic instability and cancer susceptibility, Dr. Wassarmans paper reveals how ATM mutations cause neurodegeneration.

The scientists generated a Drosophila model of A-T, in which neurodeneneration occurs in the absence of induced DNA damage as it does in human A-T patients. Thus, Dr. Wassarmans model most faithfully recapitulates neurodegeneration associated with the human disease.

Using this model, Dr. Wassarman and colleagues determined ATM functions normally to prevent neurons from re-entering the cell cycle.

At the end of the day, ATM-dependent arrest of cell growth is critical for both neuron function and tumor suppression, explains Dr. Wassarman. Furthermore, he is excited by the findings, as they point to possible therapeutic potential of CDC25 and other cell cycle inhibitors to treat A-T as well as other neurodegenerative disorders.


'/>"/>

Contact: Heather Cosel-Pieper
coselpie@cshl.edu
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1

Related biology news :

1. ESF conference probes waters mysterious interactions at molecular level
2. Power of molecular imaging reveals secrets of the heart
3. Computer simulations point to key molecular basis of cystic fibrosis
4. New edition of a classic molecular biology textbook from CSHL Press and Benjamin Cummings
5. Molecular Biology of the Cell celebrates 25 years of publication
6. Shilatifard Lab sheds light on molecular machinery required for translation of histone crosstalk
7. How molecular muscles help cells divide
8. Leading cause of death in preemies might be controlled by resetting a molecular switch
9. Pennsylvania Hospital surgeon receives grant to develop molecular cardiac surgery
10. NIH selects LIAI for major study on allergy molecular causes and possible treatments
11. Potential new therapeutic molecular target to fight cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology: